Clinical trial demonstrates non-inferior efficacy and superior safety with rivaroxaban monotherapy in stable coronary artery disease, highlighting reduced bleeding risks.
The Atrial Fibrillation and Ischemic Events with Rivaroxaban in Patients with Stable Coronary Artery Disease (AFIRE) trial demonstrated non-inferior efficacy endpoints for rivaroxaban monotherapy versus combination therapy (rivaroxaban plus a single antiplatelet) and superior safety endpoints in patients with atrial fibrillation and stable coronary artery disease.
No takes yet. Share an insight, caveat, or question.
Noda et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: